Fellowship · Pittsburgh, PA
Sponsored by UPMC Medical Education
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Neurology · 2024 · 70 citations · Paula Clemens
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
The Lancet. Neurology · 2021 · 153 citations · Paula Clemens
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
JAMA neurology · 2022 · 114 citations · Paula Clemens
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
JAMA network open · 2022 · 76 citations · Paula Clemens
First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy.
Nature medicine · 2025 · 22 citations · Paula Clemens
ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function.
Cell reports · 2022 · 88 citations · Jonathan Brent
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
Journal of neuromuscular diseases · 2021 · 96 citations · Hoda Abdel-Hamid
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
JAMA neurology · 2023 · 48 citations · Paula Clemens